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A B S T R A C T   
FOXG1 syndrome is a neurodevelopmental disorder caused by mutations in the FOXG1 gene. Here, an induced pluripotent stem cell (iPSC) line was generated from 
human dermal fibroblasts of an individual with the c.490dupG (p.Glu154fs) mutation in the FOXG1 gene. Fibroblasts were reprogrammed using non-integrating 
episomal plasmids and pluripotency marker expression was confirmed by both immunocytochemistry and quantitative PCR in the resultant iPSC line. There were no 
karyotypic abnormalities and the cell line successfully differentiated into all three germ layers. This cell line may prove useful in the study of the pathogenic 
mechanisms that underpin FOXG1 syndrome.  
1. Resource Table   
Unique stem cell line id-
entifier 
DCGi001-A 
Alternative names of st-
em cell line 
FS_E154#3 
Institution Division of Cancer and Genetics, Cardiff University School 
of Medicine, UK 
Contact information of 
distributor 
Professor Angus Clarke, ClarkeAJ@cardiff.ac.uk or 
Professor Andrew Tee, teea@cardiff.ac.uk 
Type of cell line iPSC 
Origin Human 
Additional origin info Age: 18 
Sex: Female 
Ethnicity: White European 
Cell Source Human dermal fibroblasts (HDF) 
Clonality Clonal 
Method of reprogram-
ming 
Episomal plasmid-based iPSC reprogramming 
Genetic modification YES 
Type of modification Spontaneous heterozygous mutation 
NM_005249.5:c.460dup (p,Glu154fs) 
Associated disease FOXG1 Syndrome (OMIM # 613454) 
Gene/locus FOXG1/14q12 
Method of modification N/A 
Name of transgene or r-
esistance 
N/A 
Inducible/constitutive s-
ystem 
N/A 
Date archived/stock date 06–2019 
Cell line repository/bank https://hpscreg.eu/cell-line/DCGi001-A 
Ethical approval South East Wales NHS Research Ethics Committee 10/ 
WSE03/3  
2. Resource utility 
FOXG1 syndrome is a neurodevelopmental disorder caused by mu-
tations in the FOXG1 gene. We generated iPSCs from fibroblasts of an 
individual with the c.460dupG FOXG1 mutation. This patient-derived 
cell line will be useful for modelling the pathogenic mechanisms that 
underpin FOXG1 syndrome. 
3. Resource details 
FOXG1 syndrome (originally called the congenital-onset variant of 
Rett syndrome) is a rare neurodevelopmental disorder associated with 
heterozygous mutations in the FOXG1 gene (located on chromosome 
14q12). The range of variants associated with the disorder include 
chromosomal microdeletions, larger deletions and intragenic mutations 
(missense, nonsense and frameshift). Furthermore, a subset of cases are 
associated with structural variants occurring downstream of FOXG1 
that may disrupt cis-regulation of FOXG1 expression. The clinical phe-
notype associated with FOXG1 syndrome includes severe intellectual 
disability, postnatal microcephaly, dyskinetic-hyperkinetic movement 
disorders, visual impairment, epilepsy, stereotypies, abnormal sleep 
patterns, and unexplained episodes of crying. Brain imaging of patients 
reveal structural abnormalities including hypoplasia of the corpus cal-
losum and underdevelopment of the frontal cortex (Kortum et al., 2011; 
Vegas et al., 2018). The FOXG1 gene encodes the forkhead box G1 
protein, a winged-helix transcriptional factor that is a master regulator 
of the development and regional specification of the ventral 
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telencephalon (Wong et al., 2019). Through its array of protein and 
DNA interactions FOXG1 has pleiotropic and non-redundant roles in 
brain development, reflected in the complex genotype-phenotype pre-
sentations observed (Vegas et al., 2018; Mitter et al., 2018). 
Fibroblasts were isolated from a skin biopsy taken from an 18-year 
old FOXG1 syndrome patient with a previously reported heterozygous 
pathogenic variant, c.460dupG (p.Glu154fs) (Vegas et al., 2018). iPSCs 
were generated by a non-integrating episomal plasmid-based method 
Fig. 1. Figure content described in Resource Details.  
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through expression of the reprogramming factors OCT4, SOX2, KLF4, L- 
MYC, LIN28 and p53 shRNA. A panel of iPSC-like colonies were 
manually picked after 20 days post-electroporation and expanded in 
culture over several passages for establishment as iPSC clones for fur-
ther characterisation. Amongst the panel of clones was FS_E154#3 that 
is described herein. Polymerase chain reaction (PCR) analysis per-
formed at the 10th passage using validated primers against the EBNA1 
backbone, common to all the episomal plasmids, confirmed their 
elimination from the iPSC line (Supplementary Fig. 1A). The estab-
lished FS_E154#3 iPSC line showed typical human embryonic stem cell- 
like morphology as judged by brightfield microscopy (Fig. 1A, scale bar 
is 100 μm). The line expressed the pluripotency markers OCT4 and 
SSEA4 as shown by immunocytochemistry (Fig. 1A). Quantitative real- 
time PCR analysis (qPCR) demonstrated the expression of pluripotency 
markers NANOG, OCT4 and SOX2 in the FS_E154#3 line comparable to 
a control iPSC line (sex-matched) previously generated in house 
(Fig. 1B). FS_E154#3 displayed a normal diploid 46 XX karyotype 
(passage 9, Fig. 1C), and sequencing analysis confirmed the presence of 
the heterozygous FOXG1 variant found in the parental fibroblast line 
(Fig. 1D). Short tandem repeat analysis of genomic DNA extracted from 
FS_E154#3 and parental fibroblasts confirmed matching genetic iden-
tity at the 16 loci tested. in vitro differentiation potential was verified 
using an embryoid body (EB) assay, followed by qPCR analysis of gene 
expression relative to undifferentiated cells (Fig. 1E, 12 germ layer 
markers). This detected increased expression of marker genes indicating 
the presence of cells derived from endoderm, ectoderm and mesoderm 
lineages. Furthermore, epifluorescence microscopy detected cells im-
munoreactive for ectoderm (nestin, PAX6), endoderm (AFP) and me-
soderm (αSMA) specific markers (Fig. 1F). The absence of mycoplasma 
contamination was confirmed by a PCR-based assay (Supplementary 
Fig. 1B). 
4. Materials and methods 
4.1. Reagents 
Reagents were purchased from Thermo Fisher Scientific unless 
otherwise stated. 
4.2. iPSC reprogramming and culture 
iPSC derivation was achieved by episomal reprogramming using 
plasmids pCXLE-hUL, pCXLE-hSK and pCXLE-hOCT3/4-shp53-F 
(Addgene; Supplementary Fig. 1C). Patient-derived fibroblasts (5 × 105 
cells) were electroporated with all three vectors (1 ug of each) using the 
Amaxa Human Dermal Fibroblast Nucleofector Kit and Nucleofector 2b 
(Lonza) on program U023. Nucleofected fibroblasts were plated onto 
Matrigel-coated dishes with culture conditions and iPSC colony isola-
tion according to the Essential 6 (E6) media instructions 
(MAN0007568). iPSCs were propagated in StemFlex medium and 
generally passaged at a 1:6 ratio every 4 days using ReLeSR (STEMCELL 
Technologies). 
4.3. In vitro differentiation 
EBs were formed as previously described (Ungrin et al., 2008) with 
modifications. iPSCs were dissociated using Accutase, seeded into v- 
bottom plates (Greiner; 2000 cells/well) and cultured for 24 h in 
StemFlex medium with 10 μM Y-27632 (Hello Bio) and 0.4% (w/v) PVA 
(Sigma). EBs were washed in D-PBS, resuspended in E6 media and 
transferred to low-attachment 96-well plates (Greiner). EBs were cul-
tured for a further 7 days before seeding onto Matrigel-coated 24-well 
plates and cultured in E6 media for an additional 7 days prior to ana-
lysis. 
4.4. RNA isolation, PCR and qPCR 
RNA was isolated using the RNeasy Mini Kit (QIAGEN) followed by 
DNase treatment (DNAfree kit). Complementary DNA was reverse 
transcribed from 250 ng total RNA using SuperScript IV. qPCRs were 
performed using Power SYBR Green PCR master mix and an ABI 7300 
Real Time PCR System, with data analysed by the ΔΔCt method using 
ACTNB for normalisation. PCR and qPCR parameters are available on 
request and Table 1. 
4.5. Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde for 20 mins at room 
temperature (RT), permeabilised in 0.1% (v/v) Triton X-100 for 15 
mins at 4 °C and incubated in blocking solution (10% FBS in PBS) for 30 
mins at RT. Fixed cells were incubated with primary antibodies 
(Table 2) in blocking solution (1–3 h at RT). Following three PBS wa-
shes, cells were incubated with Alexa Fluor-conjugated secondary an-
tibodies (Table 2) in blocking solution (1 h at RT), washed three times 
Table 1 
Characterization and validation.      
Classification Test Result Data  
Morphology Brightfield microscopy Normal hESC-like morphology Fig. 1 panel A 
Phenotype Qualitative analysis 
(Immunocytochemistry) 
Expression of OCT4 and SSEA4. Fig. 1 panel A 
Quantitative analysis (RT-qPCR) Expression of OCT4, SOX2 and NANOG. Fig. 1 panel B 
Genotype Karyotype (G-banding), passage 9 46XX, Resolution (≈5–10 Mb/≈450–band) Fig. 1 panel C 
Identity Microsatellite PCR (mPCR) OR Not performed  
STR analysis 16 loci matched Available with the 
authors 
Mutation analysis Sequencing Heterozygous FOXG1 c.460dupG Fig. 1 panel D 
Southern Blot OR WGS Not performed  
Microbiology and virology Mycoplasma, tested by PCR-assay Negative Supplementary Fig. 1 
Differentiation potential Embryoid body formation Expression of germ layer markers (qPCR): endoderm (GATA4, SOX17, FOXA2), 
mesoderm (RUNX1, MSX1, MYH6, NKX2.5), ectoderm (NCAM, PAX6, TUBB3, 
SOX1). 
Immunoreactivity for alpha-fetoprotein (endoderm), alpha smooth muscle actin 
(mesoderm), nestin (ectoderm) and paired box protein Pax-6 (ectoderm) by 
immunocytochemistry. 
Fig. 1 panel E and F 
Donor screening 
(OPTIONAL) 
HIV 1 + 2 Hepatitis B, Hepatitis C Not performed Not done 
Genotype additional info 
(OPTIONAL) 
Blood group genotyping Not performed Not done 
HLA tissue typing Not performed Not done 
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with PBS and mounted in Antifading Mounting Medium containing 
DAPI counterstain (Dianova). Images were acquired using a Leica DM IL 
LED Microscope with Leica DMC3000 G CCD camera. 
4.6. Sequencing 
The FOXG1 c.460dupG variant was confirmed in iPSCs and parental 
fibroblasts by Sanger Sequencing of PCR-amplified sequence from 
genomic DNA using specific primers (Table 2). DNA was isolated using 
the QIAamp DNA mini kit (QIAGEN). Sequencing reactions were per-
formed using Big Dye v3.1 chemistry and analysed by the All Wales 
Medical Genomics Service (Cardiff, UK). 
4.7. STR analysis 
STR analysis of 16 loci was performed using the Promega Powerplex 
16HS kit with amplicon detection using an Applied Biosystems 3730xl 
(undertaken by Source BioScience, Nottingham, UK). 
4.8. Karyotyping 
G-banding analysis of 20 metaphase spreads was performed by Cell 
Guidance Systems (Cambridge, UK). Fixed iPSCs for analysis were 
prepared according to service provider instructions (http://cellgs. 
e2ecdn.co.uk/Downloads/Karyotype_FixedSamples.pdf). 
4.9. Mycoplasma test 
Mycoplasma contamination was tested using the PCR-based 
Venor®GeM Classic detection kit (Minerva Biolabs) according to man-
ufacturer’s instructions. 
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Appendix A. Supplementary data 
Supplementary Fig. 1 can be found online at https://doi.org/10. 
1016/j.scr.2020.102018. 
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